A decision-analytic Markov model was developed to compare lifetime costs and outcomes for patients with stage III colon cancer treated with six adjuvant chemotherapy regimens in ZA public hospitals: ...
A Markov model was constructed to compare CMT versus RT alone for patients with early-stage ENKTCL, according to five risk groups defined by NRI model. Transition probabilities, effectiveness, and ...
This is the first cost-effectiveness model comparing COPAXONE ® and Tysabri ® for treatment of multiple sclerosis (MS) to take into consideration long-term treatment outcomes, where available, effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results